To assess the immunogenicity of the PCV13 (13 valent pneumococcal conjugated vaccine) vaccine as compared to the PPV23 (23 valent pneumococcal polysaccharide vaccine) vaccine in patients treated with chronic hemodialysis that are pre-immunized with the PPSV23 vaccine or are PPV23 vaccine naïve by measuring the ELISA and OPA (opsonophagocytic assay) titers after 4 and 52 weeks.
The immunogenicity of the PCV13 (13 valent pneumococcal conjugated vaccine) vaccine as compared to the PPV23 (23 valent pneumococcal polysaccharide vaccine) vaccine in patients treated with chronic hemodialysis that are pre-immunized with the PPV23 vaccine or are PPV23 vaccine naïve will be measured by ELISA and OPA (opsonophagocytic assay) titers after 4 and 52 weeks.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
154
Dienst Nefrologie, OLV Ziekenhuis
Aalst, Belgium
AZ Sint-Jan Brugge Oostende AV
Bruges, Belgium
Antibody response after vaccination to involved serotypes measured by OPA and ELISA
Time frame: 52 weeks after vaccination
record of side effects of vaccination
Time frame: first week after vaccination
Antibody response after vaccination to involved serotypes measured by OPA and ELISA
Time frame: 4 weeks after vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.